BIND Therapeutics and AstraZeneca Announce Worldwide Development and Commercialization Agreement for Cancer Nanomedicine

  BIND Therapeutics and AstraZeneca Announce Worldwide Development and
  Commercialization Agreement for Cancer Nanomedicine

Business Wire

CAMBRIDGE, Mass. & WILMINGTON, Del. -- April 22, 2013

BIND Therapeutics and AstraZeneca announced today that they have entered into
a strategic collaboration to develop and commercialize an Accurin^TM, a
targeted and programmable cancer nanomedicine from BIND’s Medicinal
Nanoengineering platform, based on a molecularly targeted kinase inhibitor
developed and owned by AstraZeneca.

The collaboration is based on emerging data suggesting that nanomedicines like
Accurins selectively accumulate in diseased tissues and cells, leading to
higher drug concentrations at the site of the tumor and reduced exposure to
healthy tissues.

Under the terms of the agreement, the companies will work together to complete
Investigational New Drug (IND)-enabling studies of the lead Accurin identified
from a previously-completed feasibility program. AstraZeneca will then have
the exclusive right to lead development and commercialization and BIND will
lead manufacturing during the development phase. BIND could receive upfront
and pre-approval milestone payments totaling $69 million, and more than $130
million in regulatory and sales milestones and other payments as well as
tiered single to double-digit royalties on future sales.

“We are excited to grow this collaboration with AstraZeneca, a leading global
biopharmaceutical company committed to developing innovative medicines for
patients,” said Scott Minick, President and CEO of BIND. “One year ago, BIND
started several feasibility projects with major pharmaceutical companies. Our
collaboration with AstraZeneca is the first one completed and had very
successful results. Due to the advanced nature of this program, we now plan to
move an Accurin with optimized therapeutic properties quickly into product

“AstraZeneca believes that targeted therapies which specifically address the
underlying mechanisms of disease are the future of personalized cancer
treatment,” said Susan Galbraith, Head of AstraZeneca’s Oncology Innovative
Medicines Unit. “Our oncology teams are actively exploring a range of
platforms to deliver targeted therapies, with a strategic focus on unlocking
the significant potential of nanoparticles as an approach to cancer treatment.
We view BIND’s targeted nanomedicines as a leading technology in this field.”

About Accurins™

BIND Therapeutics is discovering and developing Accurins, proprietary new
best-in-class therapeutics with superior target selectivity and the potential
to improve patient outcomes in the areas of oncology, inflammatory diseases
and cardiovascular disorders. Leveraging its proprietary Medicinal
Nanoengineering® platform, BIND develops Accurins that outperform conventional
drugs by selectively accumulating in diseased tissues and cells. The result is
higher drug concentrations at the site of action with minimal off-target
exposure, leading to markedly better efficacy and safety.

About BIND Therapeutics

BIND Therapeutics is a clinical-stage biopharmaceutical company developing a
new class of highly selective targeted and programmable therapeutics called
Accurins. BIND’s Medicinal Nanoengineering® platform enables the design,
engineering and manufacturing of Accurins with unprecedented control over drug
properties to maximize trafficking to disease sites, dramatically enhancing
efficacy while minimizing toxicities.

BIND is developing a pipeline of novel Accurins that hold extraordinary
potential to become best-in-class drugs and improve patient outcomes in the
areas of oncology, inflammatory diseases and cardiovascular disorders. BIND's
lead product candidate, BIND-014, is currently entering Phase 2 clinical
testing in cancer patients and is designed to selectively target PSMA, a
surface protein upregulated in a broad range of solid tumors. BIND also
develops Accurins in collaboration with pharmaceutical and biotechnology
partners to enable promising pipeline candidates to achieve their full
potential and to utilize selective targeting to transform the performance of
important existing drug products.

BIND is backed by leading investors Polaris Venture Partners, Flagship
Ventures, ARCH Venture Partners, NanoDimension, DHK Investments,
EndeavourVision and Rusnano. BIND was founded on proprietary technology from
the laboratories of two leaders in the field of nanomedicine, Professors
Robert Langer, David H. Koch Institute Professor of the Massachusetts
Institute of Technology (MIT) and Omid Farokhzad, Associate Professor of
Harvard Medical School. For more information, please visit the company's web
site at


The Yates Network
Kathryn Morris, 845-635-9828